-Dante Genomics Offers New Rare Disease Health Package to Help Deliver Diagnostics to the Millions of People Living with Rare Diseases and End What Can Be Years of Diagnostic Odysseys

– New offering will provide patients and their families with the necessary definitive diagnoses and allow them to move forward with a better understanding of their condition –

NEW YORK, June 5, 2023 /PRNewswire/ -- Dante Genomics, a world leader in genomics and precision medicine, today announced the launch of its rare disease healthcare package to revolutionize rare disease diagnosis with genome sequencing testing. complete.

The Rare Disease Health Package includes telemedicine pre- and post-consultations with specialist physicians, providing access to specialists who may not be available in a patient's area. Dante removes financial barriers to care by identifying potential treatments and management strategies for rare diseases. The package also prioritizes privacy and security, with a commitment not to sell personal and genomic information and to comply with all GDPR and HIPAA regulations. The clinical grade whole genome sequencing with 30X coverage used in the package ensures high precision and confidence in the results that are critical for identifying variants that may be causative of rare diseases or other conditions.

To learn more about Dante's Rare Disease Health Pack, visit dantelabs.com.

Rare diseases are a diverse group of more than 8,000 different conditions, most of which are genetic in origin, and there are an estimated 400 million people living with rare diseases worldwide. With rare diseases in particular, early diagnosis is crucial for optimal treatment, care, and genetic counseling regarding prognosis and risk of recurrence. Recent advances in genetic testing, such as whole genome sequencing (WGS), have significantly increased the likelihood of receiving a genetic diagnosis for patients with rare diseases.

"For those people living with a rare disease, an accurate diagnosis is invaluable and the first step in the treatment and management of their disease, and whole genome sequencing is the only solution to provide the diagnoses these patients desperately need." said Andrea Riposati, co-founder and CEO of Dante Genomics. "This approach can save time and money, identify potential treatment and management strategies, and provide closure for patients and their families struggling with diagnostic odysseys that can span years."

About Dante Genomics

Dante Genomics is a global genomics information company creating and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and software. The company uses its platform to deliver better patient outcomes, prevention, improved diagnostics, and personalized medicine. The company's assets include one of the largest private genomic databases with research consent, proprietary software designed to unleash the power of genomic data at scale, and proprietary processes that enable an industrial approach to genomic sequencing.

Contact: Laura D'AngeloVP of investor relationsir@dantelabs.com 39 0862 191 0671 www.dantegenomics.com

Logo - https://mma.prnewswire.com/media/2035834...

View original content: https://www.prnewswire.com/news-releases/dante-genomics-ofrece-un-nuevo-paquete-de-salud-para-enfermedades-raras-301842679.html